. "Goserelin"@en . . . "No experience of overdosage from clinical trials."@en . . . . "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels."@en . . . . . . . "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal."@en . "27.3%"@en . . . "ICI-118630"@en . . "Zoladex"@en . . . . " "@en . . "* 121 +/- 42.4 mL/min [prostate cancer with 10.8 mg depot]"@en . "Goserelin"@en . . "Humans and other mammals"@en . "Inactive orally, rapidly absorbed following subcutaneous administration."@en . "approved"@en . . . . "Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty."@en . . . "Clearance of goserelin following subcutaneous administration of a radiolabeled solution of goserelin was very rapid and occurred via a combination of hepatic and urinary excretion. More than 90% of a subcutaneous radiolabeled solution formulation dose of goserelin was excreted in urine."@en . . "4-5 hours"@en . . "Kripa S. Srivastava, Matthew R. Davis, \"Solid Phase Peptide for the Production of Goserelin.\" U.S. Patent US20100311946, issued December 09, 2010."@en . . "Goserelin acetate"@en . . . . . . . "* 44.1 \u00B1 13.6 L [subcutaneous administration of 250 mcg]"@en . . . "65807-02-5"@en . . . . . . . . . . . . . .